As new treatments for systemic lupus erythematosus and lupus nephritis enter the armamentarium, revitalizing the management ...

Chronic rhinosinusitis with nasal polyps increases the likelihood of developing coexisting conditions, such as asthma, underscoring the need for more effective, comprehensive treatments.

A 35-year-old man presents with a chief complaint of purple discoloration of his toes and associated skin lesions that have been present for the past month.

Dysregulation of the alternative complement pathway, hallmarked by isolated reduction of the serum C3 fraction, is now recognized as an additional feature of lupus nephritis. Persistent, isolated low ...

A lupus diagnosis can profoundly affect many aspects of a man’s life, from sense of identity and mental health to the way one engages with loved ones and the broader community. While lupus is often ...

Bat species facing extinction due to deadly white-nose syndrome The northern long-eared bat population, which is currently classified as threatened, faces extinction due to the wide impacts of ...

A nova explosion has been discovered shining in the constellation Lupus. Here’s how to spot it before it fades.

The US Food and Drug Administration (FDA) has approved the belimumab 200 mg/mL autoinjector for children aged 5 years of older with active lupus nephritis (LN) who are receiving standard therapy ...

The U.S. Food & Drug Administration (FDA) has granted approval for a new subcutaneous autoinjector formulation of belimumab (Benlysta®) treatment for children ages five years and older with active ...

The FDA has approved Benlysta for SC administration using an autoinjector in patients 5 years of age and older with active LN.

The US Food and Drug Administration (FDA) has approved a 200 mg/mL autoinjector formulation of belimumab (Benlysta; GSK) for children aged 5 years and older with active lupus nephritis (LN), offering ...

Dapirolizumab pegol, a novel CD40L inhibitor, is superior to placebo for achieving low disease activity and remission in systemic lupus erythematosus, according to data presented at the EULAR 2025 ...